Hassane M. Zarour
University of Pittsburgh · 262 works · 21,152 citations · h-index 53
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- Next Generation of Immunotherapy for Melanoma
- Immunotherapy of cancer in 2012
- Emerging Opportunities and Challenges in Cancer Immunotherapy
- Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
- TIGIT in cancer immunotherapy
- Melan-A/MART-1 51–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 + T cells